GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » PB Ratio

Arcutis Biotherapeutics (Arcutis Biotherapeutics) PB Ratio : 8.73 (As of May. 04, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-04), Arcutis Biotherapeutics's share price is $8.00. Arcutis Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.92. Hence, Arcutis Biotherapeutics's PB Ratio of today is 8.73.

The historical rank and industry rank for Arcutis Biotherapeutics's PB Ratio or its related term are showing as below:

ARQT' s PB Ratio Range Over the Past 10 Years
Min: 2.52   Med: 4.48   Max: 12.85
Current: 8.73

During the past 7 years, Arcutis Biotherapeutics's highest PB Ratio was 12.85. The lowest was 2.52. And the median was 4.48.

ARQT's PB Ratio is ranked worse than
88.57% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs ARQT: 8.73

During the past 12 months, Arcutis Biotherapeutics's average Book Value Per Share Growth Rate was -73.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -47.30% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Arcutis Biotherapeutics was -47.30% per year. The lowest was -47.30% per year. And the median was -47.30% per year.

Back to Basics: PB Ratio


Arcutis Biotherapeutics PB Ratio Historical Data

The historical data trend for Arcutis Biotherapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics PB Ratio Chart

Arcutis Biotherapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 4.51 3.50 4.31 3.53

Arcutis Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.31 4.83 7.30 7.03 3.53

Competitive Comparison of Arcutis Biotherapeutics's PB Ratio

For the Biotechnology subindustry, Arcutis Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcutis Biotherapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's PB Ratio falls into.



Arcutis Biotherapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Arcutis Biotherapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=8.00/0.916
=8.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Arcutis Biotherapeutics  (NAS:ARQT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Arcutis Biotherapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Executives
Masaru Matsuda officer: SVP and General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Larry Todd Edwards officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick Burnett officer: See Remarks C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Todd Franklin Watanabe director, officer: President and CEO C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Howard G. Welgus director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney officer: Senior VP, Manufacturing C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne officer: Chief Technical Officer
Kenneth A. Lock officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Matthew Richard Moore officer: SVP and Chief Business Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan director 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656